Clementia jumps on NDA plans for unmet rare bone disease

Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) climbed $4.16 (40%) to $14.50 on Oct. 24 after announcing regulatory plans for palovarotene that could put the therapy first in line to gain FDA approval for

Read the full 319 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE